Industry News Roundup
This article was originally published in The Tan Sheet
Executive Summary
‘Heal yourself’ claim nicked by FDA; Urban Moonshine’s error of omission; new tech needs old school substantiation; O2 plans big for InboxFitness; Migranade sprouts spray division; ChromaDex cashes in NeutriSci shares; GoodSense sponsors runDisney; Walgreens joins flu tracking crowd; Qualitas algal omega-3 reaches market; Islet cooks cannabidoil in business plan; and Food Advisory Committee candidates sought.
You may also be interested in...
In Brief
Ramirez appointed FTC chair; budget sequester slows FDA travel, training; ChromaDex divests BluScience brand; Omega Protein buys whey firm; Vitamin Shoppe absorbs integration costs; Vitacost trims net loss in Q4; chemical regulation champion Lautenberg to retire; USANA expands in China.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.